1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
Funding Opportunity Number: HT942526ALSRPTDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $12M total program funding.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $12M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award are due September 30, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Program is sponsored by Dept. of the Army -- USAMRAA. The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment of Amyotrophic Lateral Sclerosis.
DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award (PCTA) is sponsored by Dept. of the Army -- USAMRAA. The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment of ALS.
HRSA-27-006 and HRSA-27-007 post September 18, 2026 and both close October 19 — $711.4 million across 189 awards for service areas that already have a health center in them. The incumbent is defending. Everyone else is holding a free option.
Read articleCDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleUSDA has obligated roughly $1 billion in emergency funds against New World screwworm and awarded $105 million to 40 Grand Challenge projects from 226 proposals. On September 2, 2026, DARPA pre-released a $2.1 million SBIR topic for networked screwworm detection. Four funding streams, four eligibility regimes, four clockspeeds — and most applicants only know about one.
Read article